Maegim한국어

유나이티드제약

033270KOSPISector: Pharma & Biotech
₩17,010▼ 0.99%Market cap ₩270.6BAs of Jul 21, 2026 close · updated once daily
A
Grade A73.6 ptsTop 6% of 2,523 stocks
Financial strength
83.2
Growth momentum
40.2
Price attractiveness
86.6

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

83.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
14.3%
✓ Above median · Top 15.7% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
562.7%
✓ Above median · Top 24.6% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
17.2%
✓ Above median · Top 9.3% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
8.4%
✓ Above median · Top 17.7% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

40.2
How much did revenue grow in a year?
Revenue growth (YoY)
0.0%
✗ Below median · Top 68.3% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
3.2%
✗ Below median · Top 56.3% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-11.9%
✗ Below median · Top 64.5% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
2.8%
✗ Below median · Top 50.3% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

86.6
Is the price expensive relative to earnings?
P/E (price-to-earnings)
7.1x
✓ Above median · Top 8.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.60x
✓ Above median · Top 18.5% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15